Related Experiment Video
Updated: Mar 10, 2026

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
Published on: February 28, 2012
A Review Of Clinical Trials On LARIAT Device
Payam Safavi Naeini1, Abdi Rasekh1
1Department Of Cardiology (Drs.Abdi Rasekh And Safavi-Naeini), Texas Heart Insitute. Department Of Cardiology (Dr.Abdi Rasekh), Baylor College Of Medicine, Houston, Texas.
Insights
Patients with atrial fibrillation (AF) face a higher stroke risk. Percutaneous left atrial appendage (LAA) ligation offers a stroke prevention method for those unable to use blood thinners.
Area of Science:
- Cardiology
- Vascular Surgery
Background:
- Atrial fibrillation (AF) significantly increases embolic stroke risk (5x higher than general population).
- Left atrial appendage (LAA) is the primary source (>90%) of thrombus formation in AF patients.
- Oral anticoagulant therapy is contraindicated for some AF patients, necessitating alternative stroke prevention strategies.
Approach:
- This review evaluates the efficacy and safety of percutaneous LAA ligation.
- Focuses on LAA closure as a method to prevent thromboembolism in AF.
Key Points:
- Percutaneous LAA ligation aims to reduce stroke risk in AF patients.
- Assesses the safety and effectiveness of this minimally invasive ligation technique.
- Addresses stroke prevention in AF patients with contraindications to anticoagulation.
Conclusions:
- LAA ligation presents a viable alternative for stroke prevention in specific AF patient cohorts.
- Further research may solidify LAA ligation's role in AF management.
- Percutaneous closure of the LAA is a promising therapeutic avenue.
Abstract:
The risk of embolic stroke is 5 times higher among patients with atrial fibrillation (AF) compared with those without AF. More than 90% of thrombi form in the left atrial appendage (LAA) in AF. The purpose of this review is to determine the efficacy and safety of the left atrial appendage (LAA) closure via a percutaneous LAA ligation approach, thus preventing a stroke among patients with AF and contraindication to oral anticoagulant therapy.
More Related Videos
Related Concept Videos
Clinical Trials
There are four phases in a clinical trial. A phase one...
Clinical Trials: Overview

